Mode
Text Size
Log in / Sign up
N/A N=42 Randomized Treatment

Integrated Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)

Pain · Posttraumatic Stress Disorder

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcome: Primary: Clinician Administered Assessment of PTSD — 80.67; 70.83; 77.60; 74.73 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Behavioral Therapy - Pain (Behavioral); Cognitive Behavioral Therapy-Integrated (Behavioral); Cognitive Processing Therapy - PTSD (Behavioral); Treat as Usual (Behavioral)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
US Department of Veterans Affairs
Primary completion
Sep 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinician Administered Assessment of PTSD
80.67; 70.83; 77.60; 74.73; 75.5; 50.50

Summary

The purpose of this study is to examine the efficacy of an integrated treatment for Veterans with comorbid chronic pain and posttraumatic stress disorder (PTSD). It is hypothesized that Veterans who receive the integrated treatment will report more positive outcomes than individuals who are assigned to treatment as usual, pain treatment, or PTSD treatment.

Eligibility Criteria

Inclusion Criteria

  • Patients will be eligible for participation if they have chronic pain, defined as constant pain of at least six months duration with a neurologic or musculoskeletal etiology. Patients must also meet criteria for PTSD.
  • Stability of pain and anxiety medications will be required for two months prior to study entry and during the active treatment and TAU phase.

Exclusion Criteria

  • Patients with life threatening or acute physical illness (e.g., cancer).
  • Current alcohol or substance abuse or dependence. Veterans who have a history of alcohol or drug dependence but who have not had problematic use in the last six months will be included in the study.
  • Current psychosis or suicidal ideation.
  • Individuals seeking pain treatment such as surgical interventions will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00127413). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search